Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 14/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.70 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.70 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.67 |
| ▸ | FLT3 | P36888 | 4/20 | 0.67 |
| ▸ | AURKA | O14965 | 4/20 | 0.67 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.67 |
| ▸ | STK3 | Q13188 | 3/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.67 |
| ▸ | CSF1R | P07333 | 3/20 | 0.67 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.67 |
| ▸ | FLT4 | P35916 | 3/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457322 | 1.00 | FLT1 (1.00) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL29842618 | 1.00 | FLT1 (1.00) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6390342 | 0.86 | FLT1 (0.76) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6396736 | 0.86 | FLT1 (0.76) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6390345 | 0.86 | FLT1 (0.76) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6396732 | 0.86 | FLT1 (0.76) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6390542 | 0.85 | PDGFRB (0.77) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6390545 | 0.85 | PDGFRB (0.77) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL6392208 | 0.83 | FLT1 (0.70) | FLT1KDRFGFR1PDGFRBAURKA | |
| SCHEMBL6392213 | 0.83 | FLT1 (0.70) | FLT1KDRFGFR1PDGFRBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | claimed |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | ARES TRADING S.A. (CH) | 2009-05-28 | — | — | US | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070141140-A1 | Semi-solid formulations for immediate release intended for the oral administration of drugs | PHARMACIA ITALISA S.P.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070141140-A1 | Semi-solid formulations for immediate release intended for the oral administration of drugs | PHARMACIA ITALISA S.P.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070141140-A1 | Semi-solid formulations for immediate release intended for the oral administration of drugs | PHARMACIA ITALISA S.P.A. | 2007-06-21 | — | — | US | disclosed |
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1446117-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | FLT1 510/4885KDR 498/4885FGFR1 102/4885 |
| US-20070141140-A1 | Semi-solid formulations for immediate release intended for the oral administration of drugs | SI, LIPA, SORD | FLT1 2953/4885KDR 2684/4885FGFR1 1802/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | FLT1 6/4885KDR 71/4885FGFR1 48/4885 |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | KIT, NGF, PMP22 | FLT1 500/4885KDR 949/4885FGFR1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.